Peptides / Recovery and repair

Synthetic analog · 34 amino acids · 3,961 Da

Abaloparatide (Tymlos)

ApprovedNot banned in sport

Abaloparatide (Tymlos) is a synthetic peptide related to parathyroid hormone, approved in the US and EU for osteoporosis in selected patients. Studies in people tested it mainly on bone health, and also tracked side effects. PepBank shows 381 results on abaloparatide from 61 studies in people, and 493 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as BA-058, BA058, Abaloparatide, Eladynos, Tymlos

34 amino acids, from first to last2 changed amino acids

Evidence level: Some studies in people381 of 878 results come from studies in people.

Results in people

381

43% of 878 results

Results in animals

414

47% of 878 results

Results in lab cells

9% of 878 results

From computer models

under 1% of 878 results

Overview

Abaloparatide (Tymlos) at a glance

What it is	Synthetic analog, 34 amino acids
Approval	Approved in the US and EU (Tymlos)
In sport	Not listed as banned by WADA
Studies	157 studies with results. 121 of them gave abaloparatide, with 878 results. 381 in people414 in animals79 in lab cells4 from computer models
Best study in people	Randomized controlled trial with 511 people (2023)
Clinical trials	21 registered: 5 active or planned, 10 with posted results
Community use	A synthetic PTH-related peptide analog approved for osteoporosis in selected patients.

The science

What is abaloparatide?

A synthetic PTH-related peptide analog approved for osteoporosis in selected patients.

Amino acids in one chain

The history of abaloparatide

1993
The oldest paper on abaloparatide in PepBank is from 1993.
2007April
A registered trial of abaloparatide started (NCT00542425).

Abaloparatide (Tymlos) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 34 amino acidsFrom the first amino acid to the last

A1VS−EH5QLLH−D10+KG+KSI15Q−DL+R+R20+R−ELL−E25+KLLX+K30LHTA

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Abaloparatide (Tymlos) is a synthetic analog of 34 amino acids, with no ring, 2 changed amino acids.

Formula

C₁₇₄H₃₀₀N₅₆O₄₉

Molecular weight

3,961 g/mol

CAS number

247062-33-5

Target

Parathyroid hormone 1 receptor (gene PTH1R): agonistEvidence: official prescribing information

Development

Radius Health, Inc. Highest phase: past the trial stage (see status).

Identifiers

PubChem 76943386, UNII AVK0I6HY2U, DrugBank DB05084, UniProt P12272

Full sequence, SMILES and InChIKey

InChIKey
BVISQZFBLRSESR-XSCWXTNMSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N

See charge, composition and 3D structure on the Scientific page

The evidence

What abaloparatide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people381 of 878 results come from studies in people.

Bones and joints

724 results · 290 in people · 395 animal · 35 lab

In women with osteoporosis, transdermal abaloparatide increased spine bone density less than injected abaloparatide. Journal of bone and mineral research, 2023

Top results

In women with osteoporosis, transdermal abaloparatide increased spine bone density less than injected abaloparatide. (Journal of bone and mineral research, 2023)
In postmenopausal women with osteoporosis, abaloparatide increased femoral neck bone density by 1.55% at 3 months from baseline. (Osteoporosis international, 2026)
In men with osteoporosis, abaloparatide increased lower spine bone density more than placebo. (Journal of bone and mineral research, 2022)

Daily life and fitness

17 results · 17 in people

Among women at high fracture risk, 86% reported satisfaction with abaloparatide. JBMR plus, 2021

Top results

Among women at high fracture risk, 86% reported satisfaction with abaloparatide. (JBMR plus, 2021)
In patients with pelvic fracture, physical performance scores improved in both abaloparatide and placebo groups without group differences. (Osteoporosis international, 2026)
In women with low bone density, abaloparatide-sMTS acceptability was approximately 4.5 on a 5-point scale. (Clinical drug investigation, 2021)

Heart and blood vessels

12 results · 11 in people · 1 lab

In women with osteoporosis, abaloparatide delayed the first major cardiovascular event or heart failure versus placebo in a post hoc analysis. The Journal of clinical endocrinology and metabolism, 2020

Top results

In women with osteoporosis, abaloparatide delayed the first major cardiovascular event or heart failure versus placebo in a post hoc analysis. (The Journal of clinical endocrinology and metabolism, 2020)
In women with osteoporosis, abaloparatide increased heart rate more than placebo after the first dose. (The Journal of clinical endocrinology and metabolism, 2020)
In women with osteoporosis, systolic pressure fell by 2.7 mmHg with abaloparatide and 2.0 mmHg with teriparatide an hour after treatment. (The Journal of clinical endocrinology and metabolism, 2020)

Pain

5 results · 5 in people

In patients with pelvic fracture, pain changes did not differ between abaloparatide and placebo. Osteoporosis international, 2026

Top results

In patients with pelvic fracture, pain changes did not differ between abaloparatide and placebo. (Osteoporosis international, 2026)
Abaloparatide was linked to a strong limb pain reporting signal. (Expert opinion on drug safety, 2025)
Abaloparatide was linked to a strong back pain reporting signal. (Expert opinion on drug safety, 2025)

Kidneys and bladder

2 results · 2 in people

In a kidney transplant recipient, creatinine rose after abaloparatide began. JBMR plus, 2023

Top results

In a kidney transplant recipient, creatinine rose after abaloparatide began. (JBMR plus, 2023)
After abaloparatide stopped, the kidney transplant recipient stabilized with creatinine of 1.3-1.6 mg/dL. (JBMR plus, 2023)

Immune system and inflammation

3 results · 1 in people · 1 animal · 1 lab

In a kidney transplant recipient, new HLA antibodies appeared after abaloparatide began. JBMR plus, 2023

Top results

In a kidney transplant recipient, new HLA antibodies appeared after abaloparatide began. (JBMR plus, 2023)
In mice, abaloparatide reduced MuV- or LPS-induced inflammation in the testis and epididymis. (Proceedings of the National Academy of Sciences of the United States of America, 2021)
In lab tests with human samples, abaloparatide reduced MuV- or LPS-induced inflammatory responses in the testis and epididymis. (Proceedings of the National Academy of Sciences of the United States of America, 2021)

All 157 abaloparatide studies by area Open the Scientific page

Key abaloparatide studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study
Lewiecki et al. 2023 · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 511 people · cited by 18
7 results
People
Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization
VanDerwerker et al. 2026 · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 250 people · cited by 0
8 results
People
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
Czerwinski et al. 2022 · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 228 people · cited by 34
4 results
People
Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial
Nieves et al. 2026 · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 48 people · cited by 0
7 results
People
Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study
Matsumoto et al. 2022 · The Journal of clinical endocrinology and metabolism · cited by 34
7 results

All 157 Abaloparatide (Tymlos) studies

Abaloparatide clinical trials

ClinicalTrials.gov lists 21 trials of abaloparatide. 5 are active or planned, and 10 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Phase 3completed2,463 people

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Phase 3completed511 people

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Phase 3completed228 people

All 12 Abaloparatide (Tymlos) trials

Status and safety

Is abaloparatide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Tymlos). The FDA label for Tymlos says: “A synthetic PTH-related peptide analog approved for osteoporosis in selected patients” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Abaloparatide side effects and safety

PepBank has 84 safety results from studies of abaloparatide. 70 of them come from studies in people.

Safety results from studies (84)

In women with osteoporosis, few new fractures occurred with either transdermal or injected abaloparatide. (Journal of bone and mineral research, 2023)
In women with osteoporosis, serious heart-related adverse events were similarly frequent across groups including abaloparatide. (The Journal of clinical endocrinology and metabolism, 2020)
Among high-risk women receiving abaloparatide, 11.5% had excess calcium in urine. (Menopause, 2025)
In women aged 80 or older, adverse event rates were similar with abaloparatide and placebo. (Menopause, 2018)
In older women, adverse events were similarly frequent after abaloparatide/alendronate or placebo/alendronate. (Menopause, 2020)
In postmenopausal women, adverse events were similar with abaloparatide then alendronate and placebo then alendronate. (The Journal of clinical endocrinology and metabolism, 2018)
Bone biopsies from abaloparatide-treated patients showed normal structure. (Bone, 2017)
In women with poorer kidney function, high blood calcium occurred less often with abaloparatide than teriparatide. (Current medical research and opinion, 2019)
In men with osteoporosis, common side effects in the abaloparatide trial included injection site reaction, dizziness, nasopharyngitis, joint pain, bronchitis, high blood pressure and headache. (Journal of bone and mineral research, 2022)
In Japanese patients with osteoporosis, abaloparatide safety was similar to the earlier ACTIVE study. (The Journal of clinical endocrinology and metabolism, 2022)
In women with osteoporosis, abaloparatide caused more adverse events than placebo. Events were mild to moderate, without dose dependence. (Journal of bone and mineral metabolism, 2023)
In women with low bone density, skin redness was a common abaloparatide-sMTS side effect, mostly mild or moderate. (Clinical drug investigation, 2021)
Abaloparatide was linked to a strong joint pain reporting signal. (Expert opinion on drug safety, 2025)
Serious cardiovascular events were similar with abaloparatide and teriparatide in matched women. (Endocrine practice, 2025)
In women with osteoporosis, abaloparatide was linked to similar major cardiovascular event rates compared with teriparatide. (Osteoporosis international, 2022)
In clinic patients receiving abaloparatide, 18 patients stopped treatment because of an adverse drug reaction. (Journal of the Endocrine Society, 2022)
In the clinic, five patients stopped abaloparatide because of adverse effects. (Journal of the American Pharmacists Association, 2019)
In adverse event reports, abaloparatide was not linked to a disproportionate reporting signal for atypical femur fracture. (Scientific reports, 2023)
In adverse event reports for abaloparatide, researchers detected 99 signals, including 35 unexpected signals. (Osteoporosis international, 2023)
Tolerability accounted for 22.8% of reported reasons for stopping abaloparatide. (Osteoporosis international, 2024)
Abaloparatide was linked to the lowest cardiovascular reporting odds among studied drugs, alongside denosumab. (Mediterranean journal of rheumatology, 2026)
The patient resumed abaloparatide without abnormal biochemical results after the gluten-related problem resolved. (AACE clinical case reports, 2024)
In a kidney transplant recipient, creatinine rose after abaloparatide began. (JBMR plus, 2023)
In women with osteoporosis, mild or moderate skin reactions occurred with transdermal abaloparatide. (Journal of bone and mineral research, 2023)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
80 µg/day	Human	human	subcutaneous	12 months	Randomized trial in people · n = 250	VanDerwerker 2026
80 μg daily	Human	human	subcutaneous	12 months	Randomized trial in people · n = 228	Czerwinski 2022
80 µg daily	Human	human	subcutaneous	78 weeks	Randomized trial in people	Matsumoto 2022
40 µg daily	Human	human	subcutaneous injection	48 weeks	Randomized trial in people	Matsumoto 2023
80 µg daily	Human	human	subcutaneous injection	48 weeks	Randomized trial in people	Matsumoto 2023
80 mcg daily	Human	human	subcutaneous	18 months	Randomized trial in people · n = 1,645	McCloskey 2017
80 μg	Human	human	Not reported	18 months	Randomized trial in people · n = 500	Winzenrieth 2021
80 µg daily	Human	human	subcutaneous	6 and 18 months	Randomized trial in people · n = 500	Winzenrieth 2022
80 μg/d	Human	human	Not reported	6 months	Randomized trial in people · n = 500	Sheth 2025
80 μg	Human	human	subcutaneous	12 months	Randomized trial in people · n = 228	Dhaliwal 2024
80 μg daily	Human	human	subcutaneous	78 weeks	Randomized trial in people · n = 193	Sone 2023
40 μg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Leder 2015
80 μg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Leder 2015
80μg/d	Human	human	subcutaneous	18 months	Randomized trial in people	Moreira 2017
20 μg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Bilezikian 2018
40 μg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Bilezikian 2018
80 μg daily	Human	human	subcutaneous	24 weeks	Randomized trial in people	Bilezikian 2018
20, 40, or 80 μg	Human	human	subcutaneous	24 weeks	Randomized trial in people	Bilezikian 2018
80 µg daily	Human	human	subcutaneous	18 months	Randomized trial in people	Bilezikian 2019
80 μg daily	Human	human	subcutaneous injection	18 months	Randomized trial in people	Leder 2019
40 or 80 µg daily	Human	human	subcutaneous injection	48 weeks	Randomized trial in people	Matsumoto 2023
300 μg once daily	Human	human	intradermal	29 days	Trial in people without random groups · n = 22	Miller 2021
80 μg daily	Human	human	Not reported	3 months	Trial in people without random groups · n = 23	Dempster 2021
80 μg daily	Human	human	subcutaneous	Not reported	Reports of single patients · n = 1	Swanson 2023
80mcg daily	Human	human	Not reported	planned 12-week course	Reports of single patients · n = 1	Parikh 2020
25µg/kg/day	Animal	rat	subcutaneous	28 days	Study in live animals · n = 40	Teguh 2020
80 μg/kg five days a week	Animal	rat	subcutaneous	four weeks	Study in live animals · n = 32	Brent 2022
5 or 25 μg/kg/d	Animal	rat	subcutaneous	8 weeks	Study in live animals · n = 30	Chandler 2019
5 or 25 μg/kg	Animal	rat	subcutaneous	8 weeks	Study in live animals · n = 30	Besschetnova 2019
30 μg/kg, 5 times per week	Animal	rat	subcutaneous	6 weeks	Study in live animals · n = 28	Kataoka 2024
96 µg/kg five days a week	Animal	mouse	subcutaneous	three weeks	Study in live animals · n = 24	Brent 2021
25 μg/kg	Animal	rat	subcutaneous	8 weeks	Study in live animals · n = 20	Besschetnova 2019
25 μg/kg/day	Animal	rabbit	subcutaneous	12 weeks	Study in live animals · n = 16	Chandler 2019
10, 25, and 50 μg/kg daily	Animal	rat	subcutaneous	up to 2 years	Study in live animals	Jolette 2017
25 μg/kg daily	Animal	rat	subcutaneous	up to 2 years	Study in live animals	Jolette 2017
0.2, 1, or 5 μg/kg/day	Animal	cynomolgus monkey	subcutaneous	16 months	Study in live animals	Doyle 2018
1, 5, or 25 μg/kg/d	Animal	rat	subcutaneous	12 months	Study in live animals	Varela 2017
25 μg/kg	Animal	rat	subcutaneous	12 months	Study in live animals	Varela 2017
5 or 20 µg/kg/day	Animal	rat	subcutaneous	6 weeks	Study in live animals	Bahar 2016
5 µg/kg	Animal	rat	subcutaneous	6 weeks	Study in live animals	Bahar 2016

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes prescription use. These regimens are label information and are not community practice.

Reported routines and cautions

What people use it for

A synthetic PTH-related peptide analog approved for osteoporosis in selected patients.S1

Reported regimens

Regimens that community sources report for Abaloparatide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Adults with a labeled osteoporosis indicationOfficial label dosing of an approved product	subcutaneous injectionThe label specifies the abdominal region around the navel. It requires daily site rotation and excludes intravenous and intramuscular administration.	80 mcg per dose	once daily	Use for more than 2 years during a patient’s lifetime is not recommended. Safety and efficacy beyond 2 years have not been evaluated.	Official US prescribing information.	S1

Cautions

The label warns about osteosarcoma risk, orthostatic hypotension, and hypercalcemia.S1

Community sources

S1US Abaloparatide prescribing information (opens in a new tab)dailymed.nlm.nih.gov

Gaps

This review checked the official US label source in this record. No additional community sources were assessed. The regimen retains dose conditions and the lifetime duration limit. It does not reproduce all pen instructions.

Questions and more

Ask a question about abaloparatide

The answer links to every study it uses.

What does the evidence say about abaloparatide?Is abaloparatide tested in people?Compare with Teriparatide (PTH 1-34)Compare with Thymosin beta-4 (human)

Sources

Database: PepBank data for abaloparatide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about abaloparatide

Abaloparatide (Tymlos)

ApprovedNot banned in sport

Also known as BA-058, BA058, Abaloparatide, Eladynos, Tymlos

What it is

Synthetic analog, 34 amino acids

Approval

Approved in the US and EU (Tymlos)

In sport

Not listed as banned by WADA

Studies

157 studies with results. 121 of them gave abaloparatide, with 878 results.
381 in people414 in animals79 in lab cells4 from computer models

Best study in people

Randomized controlled trial with 511 people (2023)

Clinical trials

21 registered: 5 active or planned, 10 with posted results

Community use

A synthetic PTH-related peptide analog approved for osteoporosis in selected patients.

Dose as reported

Class

Species

Route

Duration

Design

Source

80 µg/day

Human

human

subcutaneous

12 months

Randomized trial in people · n = 250

VanDerwerker 2026

80 μg daily

Human

human

subcutaneous

12 months

Randomized trial in people · n = 228

Czerwinski 2022

80 µg daily

Human

human

subcutaneous

78 weeks

Randomized trial in people

Matsumoto 2022

40 µg daily

Human

human

subcutaneous injection

48 weeks

Randomized trial in people

Matsumoto 2023

80 µg daily

Human

human

subcutaneous injection

48 weeks

Randomized trial in people

Matsumoto 2023

80 mcg daily

Human

human

subcutaneous

18 months

Randomized trial in people · n = 1,645

McCloskey 2017

80 μg

Human

human

Not reported

18 months

Randomized trial in people · n = 500

Winzenrieth 2021

80 µg daily

Human

human

subcutaneous

6 and 18 months

Randomized trial in people · n = 500

Winzenrieth 2022

80 μg/d

Human

human

Not reported

6 months

Randomized trial in people · n = 500

Sheth 2025

80 μg

Human

human

subcutaneous

12 months

Randomized trial in people · n = 228

Dhaliwal 2024

80 μg daily

Human

human

subcutaneous

78 weeks

Randomized trial in people · n = 193

Sone 2023

40 μg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Leder 2015

80 μg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Leder 2015

80μg/d

Human

human

subcutaneous

18 months

Randomized trial in people

Moreira 2017

20 μg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Bilezikian 2018

40 μg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Bilezikian 2018

80 μg daily

Human

human

subcutaneous

24 weeks

Randomized trial in people

Bilezikian 2018

20, 40, or 80 μg

Human

human

subcutaneous

24 weeks

Randomized trial in people

Bilezikian 2018

80 µg daily

Human

human

subcutaneous

18 months

Randomized trial in people

Bilezikian 2019

80 μg daily

Human

human

subcutaneous injection

18 months

Randomized trial in people

Leder 2019

40 or 80 µg daily

Human

human

subcutaneous injection

48 weeks

Randomized trial in people

Matsumoto 2023

300 μg once daily

Human

human

intradermal

29 days

Trial in people without random groups · n = 22

Miller 2021

80 μg daily

Human

human

Not reported

3 months

Trial in people without random groups · n = 23

Dempster 2021

80 μg daily

Human

human

subcutaneous

Not reported

Reports of single patients · n = 1

Swanson 2023

80mcg daily

Human

human

Not reported

planned 12-week course

Reports of single patients · n = 1

Parikh 2020

25µg/kg/day

Animal

rat

subcutaneous

28 days

Study in live animals · n = 40

Teguh 2020

80 μg/kg five days a week

Animal

rat

subcutaneous

four weeks

Study in live animals · n = 32

Brent 2022

5 or 25 μg/kg/d

Animal

rat

subcutaneous

8 weeks

Study in live animals · n = 30

Chandler 2019

5 or 25 μg/kg

Animal

rat

subcutaneous

8 weeks

Study in live animals · n = 30

Besschetnova 2019

30 μg/kg, 5 times per week

Animal

rat

subcutaneous

6 weeks

Study in live animals · n = 28

Kataoka 2024

96 µg/kg five days a week

Animal

mouse

subcutaneous

three weeks

Study in live animals · n = 24

Brent 2021

25 μg/kg

Animal

rat

subcutaneous

8 weeks

Study in live animals · n = 20

Besschetnova 2019

25 μg/kg/day

Animal

rabbit

subcutaneous

12 weeks

Study in live animals · n = 16

Chandler 2019

10, 25, and 50 μg/kg daily

Animal

rat

subcutaneous

up to 2 years

Study in live animals

Jolette 2017

25 μg/kg daily

Animal

rat

subcutaneous

up to 2 years

Study in live animals

Jolette 2017

0.2, 1, or 5 μg/kg/day

Animal

cynomolgus monkey

subcutaneous

16 months

Study in live animals

Doyle 2018

1, 5, or 25 μg/kg/d

Animal

rat

subcutaneous

12 months

Study in live animals

Varela 2017

25 μg/kg

Animal

rat

subcutaneous

12 months

Study in live animals

Varela 2017

5 or 20 µg/kg/day

Animal

rat

subcutaneous

6 weeks

Study in live animals

Bahar 2016

5 µg/kg

Animal

rat

subcutaneous

6 weeks

Study in live animals

Bahar 2016

Context

Route

Amount

How often

How long

Agreement

Sources

Adults with a labeled osteoporosis indicationOfficial label dosing of an approved product

subcutaneous injectionThe label specifies the abdominal region around the navel. It requires daily site rotation and excludes intravenous and intramuscular administration.

80 mcg per dose

once daily

Use for more than 2 years during a patient’s lifetime is not recommended. Safety and efficacy beyond 2 years have not been evaluated.

Official US prescribing information.

Abaloparatide (Tymlos)

Abaloparatide (Tymlos) at a glance

What is abaloparatide?

The history of abaloparatide

Abaloparatide (Tymlos) structure and chemistry

What abaloparatide studies show

Bones and joints

Daily life and fitness

Heart and blood vessels

Pain

Kidneys and bladder

Immune system and inflammation

Key abaloparatide studies

Abaloparatide clinical trials

Is abaloparatide approved?

Abaloparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about abaloparatide

Related peptides

Sources

Abaloparatide (Tymlos)

Abaloparatide (Tymlos) at a glance

What is abaloparatide?

The history of abaloparatide

Abaloparatide (Tymlos) structure and chemistry

What abaloparatide studies show

Bones and joints

Daily life and fitness

Heart and blood vessels

Pain

Kidneys and bladder

Immune system and inflammation

Key abaloparatide studies

Abaloparatide clinical trials

Is abaloparatide approved?

Abaloparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about abaloparatide

Related peptides

Sources